Preparation of poly-L-lysine-based nanoparticles with pH-sensitive release of curcumin for targeted imaging and therapy of liver cancer in vitro and in vivo
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yang, Dae Hyeok | - |
dc.contributor.author | Kim, Hyun Joo | - |
dc.contributor.author | Park, Kyeongsoon | - |
dc.contributor.author | Kim, Jae Kwang | - |
dc.contributor.author | Chun, Heung Jae | - |
dc.date.available | 2019-03-07T04:45:39Z | - |
dc.date.issued | 2018-04 | - |
dc.identifier.issn | 1071-7544 | - |
dc.identifier.issn | 1521-0464 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/2267 | - |
dc.description.abstract | Poly-L-lysine (PLL) nanoparticle (NP) system was prepared for the controlled release of curcumin (CUR) by pH stimuli, and its theranostic efficacy on cancer was compared to that of CUR solution in vitro and in vivo. Deoxycholic acid (DOCA), methoxy polyethylene glycol (MPEG) and cyanine 5.5 (cy5.5) were conjugated to the amine group of PLL through condensation reaction (PLL-DOCA-MPEG-cy5.5), followed by encapsulation of CUR by dialysis method (PLL-DOCA-MPEG-cy5.5/CUR NPs). The composition, morphology and size distribution of PLL-DOCA-MPEG-cy5.5 NPs were characterized by proton nuclear magnetic resonance (H-1 NMR), transmission electron microscopy (TEM) and dynamic light scattering (DLS), respectively. In vitro tests exhibited that changes in the charge and size of the NPs at low pH led to the improved cellular uptake of CUR into human hepatoma Hep3B cell line by electrostatically absorptive endocytosis. PEGylation with MPEG was turn out to be very effective to have a prolonged blood circulation time, in turn increased the EPR effect. In addition, the incorporation of Cy5.5 into NPs provided successful biodistribution images in vivo and ex vivo. Our findings suggest that PLL-DOCA-MPEG-cy5.5/CUR NPs may have promising applications in cancer theranosis. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.title | Preparation of poly-L-lysine-based nanoparticles with pH-sensitive release of curcumin for targeted imaging and therapy of liver cancer in vitro and in vivo | - |
dc.type | Article | - |
dc.identifier.doi | 10.1080/10717544.2018.1461957 | - |
dc.identifier.bibliographicCitation | DRUG DELIVERY, v.25, no.1, pp 950 - 960 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000430210000002 | - |
dc.identifier.scopusid | 2-s2.0-85051115760 | - |
dc.citation.endPage | 960 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 950 | - |
dc.citation.title | DRUG DELIVERY | - |
dc.citation.volume | 25 | - |
dc.type.docType | Article | - |
dc.publisher.location | 영국 | - |
dc.subject.keywordAuthor | Poly-L-lysine nanoparticles | - |
dc.subject.keywordAuthor | curcumin | - |
dc.subject.keywordAuthor | PEGylation | - |
dc.subject.keywordAuthor | cyanine 5.5 | - |
dc.subject.keywordAuthor | theranosis | - |
dc.subject.keywordPlus | DRUG-DELIVERY SYSTEMS | - |
dc.subject.keywordPlus | RESPONSIVE NANOPARTICLES | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | COPOLYMERS | - |
dc.subject.keywordPlus | MICELLES | - |
dc.subject.keywordPlus | BIOAVAILABILITY | - |
dc.subject.keywordPlus | NANOCARRIER | - |
dc.subject.keywordPlus | DOXORUBICIN | - |
dc.subject.keywordPlus | WATER | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.